CAR-T cell therapy for B-cell lymphoma that returned or didn't respond
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell lymphoma like diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, or transformed follicular lymphoma.
- Your lymphoma did not respond to your last treatment or came back within 12 months of a stem cell transplant.
- You have already tried at least one anti-CD20 antibody (like rituximab) and a chemotherapy drug called anthracycline.
- Tests show your lymphoma cells have at least two of the three target proteins (CD19, CD20, or BCMA).
- You have at least one tumor that can be measured on scans.
- You are expected to live at least 12 weeks and are in good overall health (able to do daily activities, with adequate kidney, liver, lung, and heart function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
This trial tests a new CAR-T cell therapy (called ssCART-19) for people with B-cell lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells to target and kill cancer cells.
Hear when a new Non-Hodgkin Lymphoma, B-cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.